Factors influencing treatment selection and survival in advanced lung cancer

Current Oncology

Volumn 24, Issue 2, 2017, Pages e115-e122

  Tabchi, S ^a   Kassouf, E ^a   Florescu, M ^a   Tehfe, M ^a   Blais, Normand ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Advanced lung cancer; Non small cell lung cancer; Small cell lung cancer; Treatment decisions; Treatment selection

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; BRAIN METASTASIS; CANCER CENTER; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; COMORBIDITY; FEMALE; GENE MUTATION; GENE REARRANGEMENT; GENERAL CONDITION DETERIORATION; HUMAN; HUMAN TISSUE; INTENTION TO TREAT ANALYSIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PATIENT REFERRAL; RETROSPECTIVE STUDY; SMOKING; TIME TO TREATMENT; TOBACCO CONSUMPTION; TREATMENT PLANNING; TREATMENT REFUSAL;

EID: 85018273013     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.24.3355     Document Type: Article

References (41)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29. [Erratum in: CA Cancer J Clin 2014;64:364]
2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2012. Bethesda, MD: National Cancer Institute; 2015. [Available online at: http://seer.cancer.gov/ csr/1975_2012/; cited 8 May 2016]
3. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer— molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44.
4. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18:378-81.
5. Gwilliam B, Keeley V, Todd C, et al. Prognosticating in patients with advanced cancer—observational study comparing the accuracy of clinicians’ and patients’ estimates of survival. Ann Oncol 2013;24:482-8.
6. Christakis NA, Lamont EB. Extent and determinants of error in doctors’ prognoses in terminally ill patients: prospective cohort study. BMJ 2000;320:469-72.
7. Smith JL. Commentary: why do doctors overestimate? BMJ 2000;320:472-3.
8. Parkes CM. Commentary: prognoses should be based on proved indices not intuition. BMJ 2000;320:473.
9. Azzoli CG, Temin S, Giaccone G. 2011 focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage iv non-small-cell lung cancer. J Oncol Pract 2012;8:63-6.
10. Leong SS, Toh CK, Lim WT, et al. A randomized phase ii trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly. J Thorac Oncol 2007;2:230-6.
11. Baka S, Ashcroft L, Anderson H, et al. Randomized phase ii study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status
12. Lilenbaum RC. Treatment of advanced non-small-cell lung cancer in special populations. Oncology (Williston Park) 2004;18:1321-5.
13. Yee KW, Pater JL, Pho L, Zee B, Siu LL. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol 2003;21:1618-23.
14. Pujol JL, Milleron B, Molinier O, et al. Weekly paclitaxel combined with monthly carboplatin in elderly patients with advanced non-small cell lung cancer: a multicenter phase ii study. J Thorac Oncol 2006;1:328-34.
15. Jagsi R, Abrahamse P, Morrow M, Hamilton AS, Graff JJ, Katz SJ. Coordination of breast cancer care between radiation oncologists and surgeons: a survey study. Int J Radiat Oncol Biol Phys 2012;82:2072-8.
16. Keating NL, Landrum MB, Klabunde CN, et al. Adjuvant chemotherapy for stage iii colon cancer: do physicians agree about the importance of patient age and comorbidity? J Clin Oncol 2008;26:2532-7.
17. Sacher AG, Le LW, Lau A, Earle CC, Leighl NB. Real-world chemotherapy treatment patterns in metastatic nonsmall cell lung cancer: are patients undertreated? Cancer 2015;121:2562-9.
18. Davidoff AJ, Rapp T, Onukwugha E, et al. Trends in disparities in receipt of adjuvant therapy for elderly stage iii colon cancer patients: the role of the medical oncologist evaluation. Med Care 2009;47:1229-36.
19. Kassam F, Shepherd FA, Johnston M, et al. Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. J Thorac Oncol 2007;2:39-43.
20. Bouchard N, Laberge F, Raby B, Martin S, Lacasse Y. Adjuvant chemotherapy in resected lung cancer: two-year experience in a university hospital. Can Respir J 2008;15:270-4.
21. Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
22. Noonan K, Tong KM, Laskin J, et al. Referral patterns in advanced non-small cell lung cancer: impact on delivery of treatment and survival in a contemporary population based cohort. Lung Cancer 2014;86:344-9.
23. Wojcik E, Rychlik U, Stasik Z, Kulpa J, Reinfuss M, Skotnicki P. Prognostic value of laboratory factors of performance status in lung cancer patients [Polish]. Przegl Lek 2009;66:424-32.
24. Penel N, Vanseymortier M, Bonneterre ME, et al. Prognostic factors among cancer patients with good performance status screened for phase i trials. Invest New Drugs 2008;26:53-8.
25. Ando M, Ando Y, Hasegawa Y, et al. Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J Cancer 2001;85:1634-9.
26. Dajczman E, Kasymjanova G, Kreisman H, Swinton N, Pepe C, Small D. Should patient-rated performance status affect treatment decisions in advanced lung cancer? J Thorac Oncol 2008;3:1133-6.
27. Quoix E, Zalcman G, Oster JP, et al. on behalf of the Intergroupe Francophone de Cancérologie Thoracique. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced nonsmall-cell lung cancer: ifct-0501 randomised, phase 3 trial. Lancet 2011;378:1079-88.
28. Paz-Ares L, Horn L, Borghaei H, et al. Phase iii, randomized trial (CheckMate 057) of nivolumab (nivo) versus docetaxel (doc) in advanced non-squamous cell (non-sq) non-small cell lung cancer (nsclc) [abstract LBA109]. J Clin Oncol 2015;33:. [Available online at: http://meetinglibrary.asco. org/content/154634-156; cited 2 February 2017]
29. Sørensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 1993;67:773-5.
30. Mascaux C, Paesmans M, Berghmans T, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000;30:23-36.
31. Van Kleffens T, van Baarsen B, van Leeuwen E. The medical practice of patient autonomy and cancer treatment refusals: a patients’ and physicians’ perspective. Soc Sci Med 2004;58:2325-36.
32. Huchcroft SA, Snodgrass T. Cancer patients who refuse treatment. Cancer Causes Control 1993;4:179-85.
33. Hirsch FR, Bunn PA Jr. EGFR testing in lung cancer is ready for prime time. Lancet Oncol 2009;10:432-3.
34. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
35. Saliba W, Tehfe MA, Albadine R, et al. nsclc driver mutations in the Quebec population: epidemiologic and clinical evaluation [abstract e22159]. J Clin Oncol 2013;31:. [Available online at: http://meetinglibrary.asco.org/content/117534-132; cited 21 October 2015]
36. Reid JL, Hammond D, Rynard VL, Burkhalter R. Tobacco Use in Canada: Patterns and Trends, 2015 Edition. Waterloo, ON: Propel Centre for Population Health Impact, University of Waterloo; 2015
37. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum 2004;83:1-1438.
38. Ramalingam S, Pawlish K, Gadgeel S, Demers R, Kalemkerian GP. Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results database. J Clin Oncol 1998;16:651-7.
39. Salomaa ER, Sällinen S, Hiekkanen H, Liippo K. Delays in the diagnosis and treatment of lung cancer. Chest 2005;128:2282-8.
40. Brule SY, Al-Baimani K, Jonker H, et al. Palliative systemic therapy for advanced non-small cell lung cancer: investigating disparities between patients who are treated versus those who are not. Lung Cancer 2016;97:15-21.
41. Aberle DR, Adams AM, Berg CD, et al. On behalf of the National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.